article thumbnail

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

STAT

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. At issue is a medicine called posaconazole that was approved in 2006 in the U.S. And the company has refused to update the language. but is now also sold by generic companies.

article thumbnail

STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more

STAT

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. At issue is a medicine called posaconazole that was approved in 2006 in the U.S. At issue is a medicine called posaconazole that was approved in 2006 in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars

Drug Channels

As youll see below, the combination of formulary exclusion and private labels is creating an increasingly confusing and crowded biosimilar marketplace. For 2025, the Big Three PBMs shifted national formularies to favor their private-label biosimilars over Humira and its many biosimilar competitors. What do you think?

article thumbnail

The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market

Drug Channels

Private label strategies, aggressive pricing, and exclusive formulary deals have transformed what might have been a slow-crawling biosimilar introduction into a full-on pricing war. Read more » © 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

article thumbnail

The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars (rerun)

Drug Channels

As youll see below, the combination of formulary exclusion and private labels is creating an increasingly confusing and crowded biosimilar marketplace. For 2025, the Big Three PBMs shifted national formularies to favor their private-label biosimilars over Humira and its many biosimilar competitors. What do you think?

article thumbnail

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Drug Channels

During Friday's webinar, Ill share some updated thoughts on biosimilars and PBMs private label products. Below, we review the 20 products competing with Humiraincluding four private-label products marketed by in-house subsidiaries owned by CVS Health and Cigna. Click here to see the original post. All rights reserved.

article thumbnail

PBM Industry Update: Trends, Challenges, and What's Ahead (NEW Live Video Webinar)

Drug Channels

2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Emerging controversies, challenges, and threats to watch in the industry And much more! DCI reserves the right to prohibit purchasers who violate our terms from attending future DCI webinars. Unfortunately, we are unable to offer refunds. All rights reserved.